

Raoul Herbrecht

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6884241/publications.pdf>

Version: 2024-02-01

297
papers

43,083
citations

4658

85
h-index

2127

203
g-index

318
all docs

318
docs citations

318
times ranked

24649
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebral mucormycosis: neuroimaging findings and histopathological correlation. Journal of Neurology, 2022, 269, 1386-1395.	3.6	7
2	Fungal Infections Caused by <i>Kazachstania</i> spp., Strasbourg, France, 2007–2020. Emerging Infectious Diseases, 2022, 28, 29-34.	4.3	10
3	Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial. Clinical Infectious Diseases, 2022, 75, 777-785.	5.8	61
4	Systemic antifungal strategies in allogeneic hematopoietic stem cell recipients hospitalized in french hematology units: a post-hoc analysis of the cross-sectional observational AFHEM study. BMC Infectious Diseases, 2022, 22, 352.	2.9	0
5	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia, 2022, 36, 1215-1226.	7.2	19
6	Scedosporiosis/lomentosporiosis observational study (SOS): Clinical significance of <i>Scedosporium</i> species identification. Medical Mycology, 2021, 59, 486-497.	0.7	26
7	Antifungal Stewardship in Hematology: Reflection of a Multidisciplinary Group of Experts. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 35-45.	0.4	4
8	Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study. Clinical Microbiology and Infection, 2021, 27, 1644-1651.	6.0	10
9	Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia. Leukemia, 2021, 35, 1463-1474.	7.2	6
10	Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres. British Journal of Haematology, 2021, , .	2.5	2
11	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
12	Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Medical Mycology, 2020, 58, 417-424.	0.7	48
13	Methylprednisolone-induced immune thrombocytopenia. American Journal of Hematology, 2020, 95, E13-E16.	4.1	4
14	Invasive Scedosporium spp. and Lomentospora prolificans infections in pediatric patients: Analysis of 55 cases from FungiScope® and the literature. International Journal of Infectious Diseases, 2020, 92, 114-122.	3.3	23
15	Risk factors and mortality in invasive <i>Rasamsonia</i> spp. infection: Analysis of cases in the FungiScope® registry and from the literature. Mycoses, 2020, 63, 265-274.	4.0	17
16	Incidental Discovery of a COVID-19 Infection on a Reevaluation FDG PET/CT in a Patient Treated for Hodgkin Lymphoma. Clinical Nuclear Medicine, 2020, 45, 644-646.	1.3	4
17	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope® Global Registry for Emerging Fungal Infections. Journal of Infection, 2020, 81, 802-815.	3.3	20
18	Concomitant haemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukaemia. British Journal of Haematology, 2020, 189, 1054-1056.	2.5	15

#	ARTICLE	IF	CITATIONS
19	Validation by Real-life Data of the New Radiological Criteria of the Revised and Updated Consensus Definition for Invasive Fungal Diseases. <i>Clinical Infectious Diseases</i> , 2020, 71, 2773-2774.	5.8	9
20	Severe Neutropenia and Agranulocytosis Related to Antithyroid Drugs: A Study of 30 Cases Managed in A Single Reference Center. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 15.	1.4	4
21	Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis. <i>British Journal of Haematology</i> , 2020, 191, 764-774.	2.5	20
22	Invasive Pulmonary Aspergillosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 080-098.	2.1	67
23	Clinical characteristics and outcomes of invasive <i>Lomentospora prolificans</i> infections: Analysis of patients in the FungiScope [®] registry. <i>Mycoses</i> , 2020, 63, 437-442.	4.0	41
24	Antifungal Therapy: New and Evolving Therapies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 158-174.	2.1	52
25	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP [®] EBMT, EORTC [®] IG and SEIFEM survey. <i>Mycoses</i> , 2020, 63, 420-429.	4.0	7
26	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3315-3327.	3.0	30
27	BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. <i>Scientific Reports</i> , 2019, 9, 701.	3.3	26
28	Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological malignancy: a prospective, observational study in France. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 268-273.	1.8	7
29	Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2019, 9, 895.	3.3	38
30	Large deletions of the 5' region of IKZF 1 lead to haploinsufficiency in B-cell precursor acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, e155-e159.	2.5	4
31	An atypical cause of dyspnea. <i>European Journal of Internal Medicine</i> , 2019, 68, e5-e6.	2.2	0
32	Evaluation of Mass Spectrometry-Based Detection of Panfungal Serum Disaccharide for Diagnosis of Invasive Fungal Infections: Results from a Collaborative Study Involving Six European Clinical Centers. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	11
33	Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura. <i>Transfusion and Apheresis Science</i> , 2019, 58, 102665.	1.0	2
34	Prognostic factors in 264 adults with invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infection reported in the literature and FungiScope [®] . <i>Critical Reviews in Microbiology</i> , 2019, 45, 1-21.	6.1	106
35	Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera. <i>International Journal of Infectious Diseases</i> , 2019, 80, 134-136.	3.3	21
36	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1981-1989.	5.8	120

#	ARTICLE	IF	CITATIONS
37	A Core Proliferative Program Induced By B-Cell Receptor Stimulation in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2019, 134, 3777-3777.	1.4	0
38	ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 12-21.	3.0	91
39	Evaluation of Two Commercial Real-Time PCR Kits for <i>Aspergillus</i> DNA Detection in Bronchoalveolar Lavage Fluid in Patients with Invasive Pulmonary Aspergillosis. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 298-306.	2.8	16
40	Diagnosis and management of <i>Aspergillus</i> diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. <i>Clinical Microbiology and Infection</i> , 2018, 24, e1-e38.	6.0	942
41	Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity. <i>Journal De Mycologie Medicale</i> , 2018, 28, 8-14.	1.5	28
42	Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity. <i>Journal De Mycologie Medicale</i> , 2018, 28, 15-22.	1.5	25
43	Neutrophils differentially attenuate immune response to <i>Aspergillus</i> infection through complement receptor 3 and induction of myeloperoxidase. <i>Cellular Microbiology</i> , 2018, 20, e12798.	2.1	6
44	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. <i>Journal of Infection</i> , 2018, 76, 20-37.	3.3	125
45	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patientâ€Level Analysis of Multiple Randomized Trials (SEAL). <i>Journal of Clinical Oncology</i> , 2018, 36, 2593-2602.	1.6	59
46	18F-FDG PET/CT for invasive fungal infection in immunocompromised patients. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 613-622.	0.5	51
47	Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura. <i>Vox Sanguinis</i> , 2018, 113, 459-467.	1.5	12
48	Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. <i>Mycoses</i> , 2018, 61, 868-876.	4.0	9
49	Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis. <i>Current Medical Research and Opinion</i> , 2018, 34, 2187-2195.	1.9	9
50	Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study. <i>Infectious Diseases and Therapy</i> , 2018, 7, 309-325.	4.0	5
51	Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. <i>Annals of Oncology</i> , 2018, 29, 1822-1827.	1.2	61
52	Traitement des infections fongiques invasives et superficielles. , 2018, , 893-924.e1.		1
53	ZAP-70 Expression in Non Tumoral B Cells: Role in B Tolerance Breakdown?. <i>Blood</i> , 2018, 132, 1114-1114.	1.4	1
54	Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 510-519.	9.1	366

#	ARTICLE	IF	CITATIONS
55	18F-FDG PET/CT for the Diagnosis of Malignant and Infectious Complications After Solid Organ Transplantation. Nuclear Medicine and Molecular Imaging, 2017, 51, 58-68.	1.0	21
56	Idiosyncratic drug-induced neutropenia & agranulocytosis. QJM - Monthly Journal of the Association of Physicians, 2017, 110, hcw220.	0.5	25
57	Assessment of high-priced systemic antifungal prescriptions. Médecine Et Maladies Infectieuses, 2017, 47, 382-388.	5.0	5
58	Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. Journal of Antimicrobial Chemotherapy, 2017, 72, 2368-2377.	3.0	24
59	New pharmacological opportunities for the treatment of invasive mould diseases. Journal of Antimicrobial Chemotherapy, 2017, 72, i48-i58.	3.0	20
60	Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients? authors' response. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw580.	3.0	13
61	Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. Journal of Antimicrobial Chemotherapy, 2017, 72, 2359-2367.	3.0	65
62	Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial. Intensive Care Medicine, 2017, 43, 1613-1625.	8.2	26
63	Anticorps anti-pseudo-PCNA de type 1 (anti-SG2NA): cherchez un cancer, pas le lupus. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 226-230.	0.0	0
64	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 2017, 102, 433-444.	3.5	468
65	Brain abscesses caused by Cryptococcus neoformans in a lung transplant patient: A case report and review of the literature. Transplant Infectious Disease, 2017, 19, e12787.	1.7	4
66	FungiScope™ Global Emerging Fungal Infection Registry. Mycoses, 2017, 60, 508-516.	4.0	47
67	History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs. Journal of Clinical Medicine, 2017, 6, 92.	2.4	6
68	Simultaneous primary invasive cutaneous aspergillosis in two preterm twins: case report and review of the literature. BMC Infectious Diseases, 2017, 17, 535.	2.9	20
69	Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy. JAMA - Journal of the American Medical Association, 2017, 318, 2099.	7.4	120
70	Magnetic Resonance Imaging of Cerebral Aspergillosis: Imaging and Pathological Correlations. PLoS ONE, 2016, 11, e0152475.	2.5	66
71	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 63, e1-e60.	5.8	1,861
72	Multimodality Diagnosis Approach of Cardiac Aspergillosis. Echocardiography, 2016, 33, 663-665.	0.9	2

#	ARTICLE	IF	CITATIONS
73	ECIL guidelines for the diagnosis of <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2386-2396.	3.0	226
74	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, 433-442.	5.8	295
75	Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 Cases. <i>Drugs - Real World Outcomes</i> , 2016, 3, 393-399.	1.6	9
76	ECIL guidelines for preventing <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2397-2404.	3.0	211
77	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet</i> , The, 2016, 387, 760-769.	13.7	695
78	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	9.1	528
79	Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). <i>Clinical Microbiology and Infection</i> , 2016, 22, 810.e1-810.e8.	6.0	168
80	Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE. <i>Joint Bone Spine</i> , 2016, 83, 330-334.	1.6	5
81	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. <i>Blood</i> , 2016, 128, 3027-3027.	1.4	5
82	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. <i>Blood</i> , 2016, 128, 4196-4196.	1.4	1
83	Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors. <i>PLoS ONE</i> , 2016, 11, e0156679.	2.5	38
84	Rare oral metastasis from a probable large-cell neuroendocrine carcinoma of the lung. <i>Medecine Buccale Chirurgie Buccale</i> , 2016, 22, 49-54.	0.1	2
85	Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).. <i>Haematologica</i> , 2015, 100, 1587-1594.	3.5	110
86	Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. <i>Mycoses</i> , 2015, 58, 58-64.	4.0	31
87	Bilberry extract (Antho 50) selectively induces redox-sensitive caspase 3-related apoptosis in chronic lymphocytic leukemia cells by targeting the Bcl-2/Bad pathway. <i>Scientific Reports</i> , 2015, 5, 8996.	3.3	39
88	Long-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001 (EMERGE) pivotal trial. <i>British Journal of Haematology</i> , 2015, 170, 496-503.	2.5	34
89	Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. <i>Thrombosis and Haemostasis</i> , 2015, 113, 414-425.	3.4	10
90	Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients. <i>Clinical Therapeutics</i> , 2015, 37, 1317-1328.e2.	2.5	26

#	ARTICLE	IF	CITATIONS
91	Combination Antifungal Therapy for Invasive Aspergillosis. <i>Annals of Internal Medicine</i> , 2015, 162, 81-89.	3.9	376
92	Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3116-3123.	3.0	118
93	Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. <i>Clinical Infectious Diseases</i> , 2015, 60, 713-720.	5.8	75
94	Multicentric Analyses of the CD148, CD180, and CD200 Combination for the Diagnosis of Mature B-Cell Neoplasm Using Flow Cytometry. <i>Blood</i> , 2015, 126, 2662-2662.	1.4	4
95	Posttraumatic Mucormycosis. <i>Medicine (United States)</i> , 2014, 93, 395-404.	1.0	81
96	Voriconazole or Amphotericin B as Primary Therapy Yields Distinct Early Serum Galactomannan Trends Related to Outcomes in Invasive Aspergillosis. <i>PLoS ONE</i> , 2014, 9, e90176.	2.5	18
97	Improvement in the outcome of invasive fusariosis in the last decade. <i>Clinical Microbiology and Infection</i> , 2014, 20, 580-585.	6.0	151
98	Interest of the CD148, CD180 and CD200 Combination in Flow Cytometry Analyses for Mature B-Cell Neoplasms Diagnosis. <i>Blood</i> , 2014, 124, 5407-5407.	1.4	0
99	Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2013, 24, 2618-2623.	1.2	48
100	Severe methotrexate toxicity due to a concomitant administration of ciprofloxacin. <i>MÃ©decine Et Maladies Infectieuses</i> , 2013, 43, 39-41.	5.0	12
101	Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, iii5-iii16.	3.0	29
102	Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. <i>Leukemia</i> , 2013, 27, 503-507.	7.2	54
103	Invasive infections due to <i>Candida norvegensis</i> and <i>Candida inconspicua</i> : report of 12 cases and review of the literature. <i>Medical Mycology</i> , 2013, 51, 795-799.	0.7	43
104	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. <i>Haematologica</i> , 2013, 98, e127-e130.	3.5	99
105	Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). <i>Haematologica</i> , 2013, 98, 492-504.	3.5	282
106	An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1655-1659.	3.0	20
107	High Incidence but Low Burden of Coronaviruses and Preferential Associations between Respiratory Viruses. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3039-3046.	3.9	38
108	Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas. <i>Leukemia</i> , 2013, 27, 1748-1750.	7.2	23

#	ARTICLE	IF	CITATIONS
109	A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm. <i>Leukemia</i> , 2013, 27, 1186-1188.	7.2	33
110	Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib. <i>Blood</i> , 2013, 122, 3057-3057.	1.4	2
111	Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review. <i>Blood</i> , 2013, 122, 4820-4820.	1.4	0
112	Disseminated Trichosporon mycotoxinivorans, Aspergillus fumigatus, and Scedosporium apiospermum Coinfection after Lung and Liver Transplantation in a Cystic Fibrosis Patient. <i>Journal of Clinical Microbiology</i> , 2012, 50, 4168-4170.	3.9	52
113	Febrile pancytopenia as uncommon presentation of disseminated toxoplasmosis after BMT. <i>Bone Marrow Transplantation</i> , 2012, 47, 301-303.	2.4	8
114	Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders. <i>Blood Cancer Journal</i> , 2012, 2, e88-e88.	6.2	5
115	Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2506-2513.	3.0	63
116	Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2731-2738.	3.0	41
117	Earlier Diagnosis of Angioinvasive Pulmonary Mold Disease: Is Computed Tomography Pulmonary Angiography a New Step?. <i>Clinical Infectious Diseases</i> , 2012, 54, 617-620.	5.8	5
118	Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. <i>British Journal of Haematology</i> , 2012, 159, 67-77.	2.5	100
119	ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). <i>Clinical Microbiology and Infection</i> , 2012, 18, 53-67.	6.0	280
120	Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2330-2336.	3.9	74
121	Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). <i>Clinical Microbiology and Infection</i> , 2012, 18, E396-E400.	6.0	68
122	ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. <i>Clinical Microbiology and Infection</i> , 2012, 18, 1-8.	6.0	91
123	ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. <i>Clinical Microbiology and Infection</i> , 2012, 18, 9-18.	6.0	310
124	ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. <i>Clinical Microbiology and Infection</i> , 2012, 18, 19-37.	6.0	977
125	ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. <i>Clinical Microbiology and Infection</i> , 2012, 18, 38-52.	6.0	264
126	ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. <i>Clinical Microbiology and Infection</i> , 2012, 18, 68-77.	6.0	81

#	ARTICLE	IF	CITATIONS
127	Risk stratification for invasive aspergillosis in immunocompromised patients. Annals of the New York Academy of Sciences, 2012, 1272, 23-30.	3.8	112
128	Breakthrough invasive mould infections in patients treated with caspofungin. Journal of Infection, 2012, 64, 424-429.	3.3	63
129	Ruxolitinib Therapy in Myelofibrosis: Analysis of 241 Patients Treated in Compassionate Use (French) Tj ETQq1 1 0.784314 rgBT /Over 2841-2841.	1.4	2
130	Strong Cell Surface Expression of the Toll-Like Receptor Homolog CD180 Identifies Circulating Cells of Marginal Zone Lymphoma From Other B-Cell Malignancies. Blood, 2012, 120, 1542-1542.	1.4	0
131	Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2011, 52, 620-628.	1.3	21
132	Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Review of Clinical Pharmacology, 2011, 4, 743-750.	3.1	50
133	European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 2009 Update. Bone Marrow Transplantation, 2011, 46, 709-718.	2.4	402
134	A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. Blood, 2011, 118, e1-e15.	1.4	22
135	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica, 2011, 96, 1136-1143.	3.5	84
136	Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses, 2011, 54, e449-55.	4.0	49
137	A retrospective series of gut aspergillosis in haematology patients. Clinical Microbiology and Infection, 2011, 17, 588-594.	6.0	87
138	European expert opinion on the management of invasive candidiasis in adults. Clinical Microbiology and Infection, 2011, 17, 1-12.	6.0	113
139	Towards novel paradigms for cancer therapy. Oncogene, 2011, 30, 1-20.	5.9	112
140	Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. International Journal of Clinical Pharmacy, 2011, 33, 905-908.	2.1	7
141	Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system. Journal of Medical Economics, 2011, 14, 28-35.	2.1	19
142	Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. Journal of Antimicrobial Chemotherapy, 2011, 66, i25-i35.	3.0	35
143	Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 2011, 66, i5-i14.	3.0	178
144	CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study. Blood, 2011, 118, 1605-1605.	1.4	2

#	ARTICLE	IF	CITATIONS
145	Antifungal Therapy in Patients with Hematological Malignancies. , 2011, , 569-588.		0
146	Cola beverage and delayed elimination of methotrexate. British Journal of Clinical Pharmacology, 2010, 70, 762-764.	2.4	23
147	Successful Treatment of a Granulocytic Sarcoma of the Uterine Cervix in Complete Remission at Six-Year Follow-Up. Journal of Oncology, 2010, 2010, 1-3.	1.3	9
148	Early Proinflammatory Cytokines and C-reactive Protein Trends as Predictors of Outcome in Invasive Aspergillosis. Journal of Infectious Diseases, 2010, 202, 1454-1462.	4.0	52
149	Lessons from a Case of Oromandibular Mucormycosis Treated with Surgery and a Combination of Amphotericin B Lipid Formulation plus Caspofungin. Acta Haematologica, 2010, 124, 98-102.	1.4	20
150	International Retrospective Analysis of 73 Cases of Invasive Fusariosis Treated with Voriconazole. Antimicrobial Agents and Chemotherapy, 2010, 54, 4446-4450.	3.2	158
151	Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B. Journal of Antimicrobial Chemotherapy, 2010, 65, 114-117.	3.0	17
152	Forty-one recent cases of invasive zygomycosis from a global clinical registry. Journal of Antimicrobial Chemotherapy, 2010, 65, 296-302.	3.0	169
153	Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis. Current Medical Research and Opinion, 2010, 26, 2457-2464.	1.9	7
154	Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplantation, 2010, 45, 1227-1233.	2.4	130
155	Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: An useful tool for diagnosis and assessment of outcome in clinical trials. European Journal of Radiology, 2010, 74, e172-e175.	2.6	62
156	Bendamustine Induces Higher Remission Rates, Prolongs Progression Free Survival as Well as Time to Next Treatment, and Improves Overall Survival for Patients In Complete Remission without Compromising Quality of Life When Compared to Chlorambucil In First Line Treatment of Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2449-2449.	1.4	5
157	Zygomycosis After Allogeneic Hematopoietic Stem Cell Transplantation: A French Multicenter Cohort Study (2003-2008). Blood, 2010, 116, 1263-1263.	1.4	8
158	Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Research, 2010, 30, 963-5.	1.1	28
159	An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. Journal of Antimicrobial Chemotherapy, 2009, 64, 1274-1281.	3.0	135
160	Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Annals of Oncology, 2009, 20, 1985-1992.	1.2	64
161	A Multicenter, Double-blind Trial of a High-Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis. Clinical Infectious Diseases, 2009, 48, 1676-1684.	5.8	196
162	Association of Mannose-binding Lectin Deficiency with Acute Invasive Aspergillosis in Immunocompromised Patients. Clinical Infectious Diseases, 2009, 49, 1486-1491.	5.8	75

#	ARTICLE	IF	CITATIONS
163	Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine. International Journal of Clinical Pharmacy, 2009, 31, 619-621.	1.4	17
164	Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia, 2009, 23, 617-619.	7.2	30
165	Proteomic Analysis of Malignant B-Cell Derived Microparticles Reveals CD148 as a Potentially Useful Antigenic Biomarker for Mantle Cell Lymphoma Diagnosis. Journal of Proteome Research, 2009, 8, 3346-3354.	3.7	51
166	Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2009, 27, 4378-4384.	1.6	403
167	Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology, 2009, 27, 3822-3829.	1.6	625
168	Drug-Drug Interactions of Triazole Antifungal Agents in Multimorbid Patients and Implications for Patient Care. Current Drug Metabolism, 2009, 10, 395-409.	1.2	60
169	Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.. Blood, 2009, 114, 2367-2367.	1.4	29
170	Changes in causes of death over time after treatment for invasive aspergillosis. Cancer, 2008, 112, 2309-2312.	4.1	77
171	Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. Cancer Genetics and Cytogenetics, 2008, 180, 51-55.	1.0	30
172	The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals. Clinical Pharmacokinetics, 2008, 47, 779-792.	3.5	104
173	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	5.8	4,375
174	Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2008, 46, 327-360.	5.8	2,432
175	Tratamiento de la Aspergilosis: Guías para la práctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América (IDSA). Clinical Infectious Diseases, 2008, 46, T1-T36.	5.8	4
176	Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis. Clinical Infectious Diseases, 2008, 47, 1176-1184.	5.8	307
177	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clinical Infectious Diseases, 2008, 47, 674-683.	5.8	368
178	Â-D-Glucan Detection Test: A Step Toward Preemptive Therapy for Fungal Infections in Leukemic Patients?. Clinical Infectious Diseases, 2008, 46, 886-889.	5.8	26
179	Prevention and Early Treatment of Invasive Fungal Infection in Patients with Cancer and Neutropenia and in Stem Cell Transplant Recipients in the Era of Newer Broad-Spectrum Antifungal Agents and Diagnostic Adjuncts. Clinical Infectious Diseases, 2007, 44, 402-409.	5.8	166
180	Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Clinical Infectious Diseases, 2007, 44, 1289-1297.	5.8	663

#	ARTICLE	IF	CITATIONS
181	Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial. Clinical Infectious Diseases, 2007, 44, 2-12.	5.8	724
182	Reply to Wolf et al.. Clinical Infectious Diseases, 2007, 45, 668-669.	5.8	0
183	Reply to Denning. Clinical Infectious Diseases, 2007, 45, 1108-1110.	5.8	5
184	Reply to Verweij et al. Clinical Infectious Diseases, 2007, 44, 1667-1668.	5.8	5
185	HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. International Journal of Biochemistry and Cell Biology, 2007, 39, 1500-1509.	2.8	44
186	Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign. Clinical Infectious Diseases, 2007, 44, 373-379.	5.8	524
187	[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography for Early Evaluation of Treatment Efficacy in Advanced Non-Hodgkin Lymphoma of Uterine Corpus: A Case Report. Clinical Lymphoma and Myeloma, 2007, 7, 421-424.	1.4	0
188	Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. European Journal of Cancer, Supplement, 2007, 5, 49-59.	2.2	60
189	Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies. Cancer, 2007, 110, 2740-2746.	4.1	163
190	Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transplant Infectious Disease, 2007, 9, 182-188.	1.7	25
191	13q deletions in B-cell lymphoproliferative disorders: frequent association with translocation. Cancer Genetics and Cytogenetics, 2007, 174, 151-160.	1.0	12
192	CHOP-R (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab) Compared to CPOP-R (Cyclophosphamide, Pixantrone, Vincristine, Prednisone, Rituximab) in First-Line Therapy of Diffuse Large B Cell Lymphoma (DLBCL): An Interim Analysis.. Blood, 2007, 110, 3445-3445.	1.4	6
193	EXTEND PIX301: A Phase III Randomized Trial of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Monotherapy in Patients with Relapsed, Aggressive Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2006, 7, 152-154.	1.4	14
194	Clinical pharmacokinetics of voriconazole. International Journal of Antimicrobial Agents, 2006, 27, 274-284.	2.5	129
195	Managing the challenges of invasive fungal infections. International Journal of Antimicrobial Agents, 2006, 27, 1-2.	2.5	7
196	Antifungal combination treatment: a future perspective. International Journal of Antimicrobial Agents, 2006, 27, 25-30.	2.5	35
197	Discovery and Identification of Potential Biomarkers in a Prospective Study of Chronic Lymphoid Malignancies Using SELDI-TOFâ™MS. Journal of Proteome Research, 2006, 5, 2258-2269.	3.7	46
198	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood, 2006, 107, 3053-3057.	1.4	390

#	ARTICLE	IF	CITATIONS
199	Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization. <i>Proteomics</i> , 2006, 6, 153-171.	2.2	114
200	Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. <i>British Journal of Haematology</i> , 2006, 134, 602-612.	2.5	50
201	Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. <i>Journal of Infection</i> , 2006, 52, 67-74.	3.3	48
202	Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH. <i>Cancer Genetics and Cytogenetics</i> , 2006, 168, 133-145.	1.0	22
203	Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. <i>Cancer</i> , 2006, 107, 2888-2897.	4.1	200
204	Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-hodgkin's lymphoma after failure of the LNH 84 regimen. <i>Hematological Oncology</i> , 2006, 9, 253-257.	1.7	5
205	Clinical antifungal efficacy trials in invasive aspergillosis: Consensus standards for trial design and room for improvement. <i>Medical Mycology</i> , 2006, 44, 289-294.	0.7	67
206	Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions. <i>Clinical Infectious Diseases</i> , 2006, 42, 1398-1403.	5.8	290
207	Posaconazole as Salvage Therapy for Zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 126-133.	3.2	523
208	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. <i>Clinical Infectious Diseases</i> , 2006, 43, 1031-1039.	5.8	3
209	Mycograb for the Treatment of Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2006, 43, 1083-1083.	5.8	24
210	Prognostic Factors for Death Due to Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation: A 1-Year Retrospective Study of Consecutive Patients at French Transplantation Centers. <i>Clinical Infectious Diseases</i> , 2006, 42, 955-963.	5.8	119
211	Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2006, 108, 529-529.	1.4	6
212	Long Term Efficacy of Rituximab in B-Cell Post Transplantation Lymphoproliferative Disorders (B-PTLD): Update of the Multicenter, Open Label, Phase II Trial (M39037 TRIAL).. <i>Blood</i> , 2006, 108, 2764-2764.	1.4	5
213	Prognostic Factors for Survival in Invasive Aspergillosis in Adult Oncohematological Patients.. <i>Blood</i> , 2006, 108, 2852-2852.	1.4	0
214	Voriconazole for Invasive Bone Aspergillosis: A Worldwide Experience of 20 Cases. <i>Clinical Infectious Diseases</i> , 2005, 40, 1141-1147.	5.8	117
215	<i>Saccharomyces cerevisiae</i> Fungemia: An Adverse Effect of <i>Saccharomyces boulardii</i> Probiotic Administration. <i>Clinical Infectious Diseases</i> , 2005, 40, 1635-1637.	5.8	74
216	Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome. <i>Clinical Infectious Diseases</i> , 2005, 41, 1448-1452.	5.8	106

#	ARTICLE	IF	CITATIONS
217	Management of systemic fungal infections: alternatives to itraconazole. Journal of Antimicrobial Chemotherapy, 2005, 56, i39-i48.	3.0	31
218	Can combination salvage therapy for invasive aspergillosis improve patient outcome?. Nature Clinical Practice Oncology, 2005, 2, 186-187.	4.3	0
219	Invasive aspergillosis in the hematologic and immunologic patient: new findings and key questions in leukemia. Medical Mycology, 2005, 43, 239-242.	0.7	14
220	Epidemiological study of invasive pulmonary aspergillosis in a haematology unit by molecular typing of environmental and patient isolates of Aspergillus fumigatus. Journal of Hospital Infection, 2005, 60, 61-68.	2.9	45
221	Liposomal Amphotericin B (L-AMB) as Initial Therapy for Invasive Filamentous Fungal Infections (IFFI): A Randomized, Prospective Trial of a High Loading Regimen vs. Standard Dosing (AmBiLoad Trial).. Blood, 2005, 106, 3222-3222.	1.4	21
222	Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study.. Blood, 2005, 106, 677-677.	1.4	3
223	Invasive Pulmonary Aspergillosis. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 191-202.	2.1	29
224	Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B. Antimicrobial Agents and Chemotherapy, 2004, 48, 4808-4812.	3.2	52
225	The Design of Clinical Trials That Evaluate Antifungal Prophylaxis and Combination Therapy: Introduction and Overview. Clinical Infectious Diseases, 2004, 39, S165-S169.	5.8	8
226	All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Annals of Oncology, 2004, 15, 1790-1797.	1.2	52
227	A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. Journal of Antimicrobial Chemotherapy, 2004, 54, 456-464.	3.0	16
228	Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. International Journal of Clinical Practice, 2004, 58, 612-624.	1.7	130
229	Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist. European Radiology, 2004, 14, 2030-2037.	4.5	12
230	Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. Journal of Heart and Lung Transplantation, 2004, 23, 1451-1454.	0.6	66
231	An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. European Journal of Cancer, 2004, 40, 1314-1319.	2.8	39
232	Voriconazole: therapeutic review of a new azole antifungal. Expert Review of Anti-Infective Therapy, 2004, 2, 485-497.	4.4	103
233	Bendamustine Versus Chlorambucil in Treatment-Naïve B-CLL Patients.. Blood, 2004, 104, 4817-4817.	1.4	2
234	Hospital Resource Utilization in Acute Invasive Aspergillosis (AIA) Patients (Pts) Treated with Voriconazole (VOR) or Amphotericin B (CAB).. Blood, 2004, 104, 88-88.	1.4	1

#	ARTICLE	IF	CITATIONS
235	Management of Acute Myeloid Leukemia (AML) in First Relapse: Retrospective Analysis about 101 Adults Cases Receiving Homogeneous First-Line Therapy. Impact of Prognostic Factors and Treatment.. Blood, 2004, 104, 882-882.	1.4	0
236	Caspofungin: the first representative of a new antifungal class. Journal of Antimicrobial Chemotherapy, 2003, 51, 513-521.	3.0	173
237	A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clinical Therapeutics, 2003, 25, 1295-1320.	2.5	163
238	The lipid formulations of amphotericin B. Expert Opinion on Pharmacotherapy, 2003, 4, 1277-1287.	1.8	82
239	Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin's Lymphoma: Results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study. Journal of Clinical Oncology, 2003, 21, 4402-4406.	1.6	216
240	Introduction the Forum Report on Advances in the Design of Antifungal Clinical Trials. Clinical Infectious Diseases, 2003, 36, S112-S112.	5.8	0
241	Forum Report: Issues in the Evaluation of Diagnostic Tests, Use of Historical Controls, and Merits of the Current Multicenter Collaborative Groups. Clinical Infectious Diseases, 2003, 36, S123-S127.	5.8	10
242	Epidemiology and Risk Factors for Gram-Positive Coccal Infections in Neutropenia: Toward a More Targeted Antibiotic Strategy. Clinical Infectious Diseases, 2003, 36, 149-158.	5.8	103
243	Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 2003, 102, 4284-4289.	1.4	306
244	Forum Report: Issues in the Design of Trials of Drugs for the Treatment of Invasive Aspergillosis. Clinical Infectious Diseases, 2003, 36, S113-S116.	5.8	7
245	Forum Report: Issues in Clinical Trials of Empirical Antifungal Therapy in Treating Febrile Neutropenic Patients. Clinical Infectious Diseases, 2003, 36, S117-S122.	5.8	54
246	Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis. Clinical Infectious Diseases, 2002, 34, 563-571.	5.8	807
247	Successful Outcome of Treatment of a Disseminated Infection Due to Fusarium dimerum in a Leukemia Patient. Journal of Clinical Microbiology, 2002, 40, 1100-1102.	3.9	34
248	Voriconazole versus Amphotericin B for Invasive Aspergillosis. New England Journal of Medicine, 2002, 347, 2080-2081.	27.0	29
249	AspergillusGalactomannan Detection in the Diagnosis of Invasive Aspergillosis in Cancer Patients. Journal of Clinical Oncology, 2002, 20, 1898-1906.	1.6	380
250	CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. New England Journal of Medicine, 2002, 346, 235-242.	27.0	4,928
251	Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis. New England Journal of Medicine, 2002, 347, 408-415.	27.0	3,048
252	Acremonium strictum Pulmonary Infection in a Leukemic Patient Successfully Treated with Posaconazole After Failure of Amphotericin B. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 814-817.	2.9	50

#	ARTICLE	IF	CITATIONS
253	Fatal <i>Aspergillus fumigatus</i> Myositis in an Immunocompetent Patient. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001, 20, 810-813.	2.9	18
254	Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy. <i>Annals of Internal Medicine</i> , 2001, 135, 412.	3.9	299
255	Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma. <i>The Hematology Journal</i> , 2001, 2, 279-285.	1.4	10
256	Tumor necrosis factor α release is a major biological event associated with rituximab treatment. <i>The Hematology Journal</i> , 2001, 2, 378-384.	1.4	88
257	Randomized Comparison of ACVBP and m-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 1309-1315.	1.6	55
258	Invasive Aspergillosis as an Opportunistic Infection in Nonallografted Patients with Multiple Myeloma: A European Organization for Research and Treatment of Cancer. <i>Clinical Infectious Diseases</i> , 2000, 30, 41-46.	5.8	58
259	Hearing loss due to acute leukemia. <i>American Journal of Medicine</i> , 2000, 109, 509-510.	1.5	5
260	Fungal Infections in Patients With Neutropenia. <i>Drugs and Aging</i> , 2000, 17, 339-351.	2.7	23
261	Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. <i>Transplant Infectious Disease</i> , 1999, 1, 273-283.	1.7	101
262	Prognostic factors in ovarian carcinoma in complete histologic remission at second-look surgery. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 231-237.	2.5	4
263	Isolated Renal <i>Aspergillus</i> Abscess in an AIDS Patient with a Normal CD4+ Cell Count on Highly Active Antiretroviral Therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 137-141.	2.9	18
264	Emergence of Unusual Cytogenetic Abnormalities under Interferon-Alpha Therapy in Patients with Chronic Myelogenous Leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1999, 113, 172-176.	1.0	9
265	Safety and Efficacy of Amphotericin B Colloidal Dispersion. <i>Chemotherapy</i> , 1999, 45, 67-76.	1.6	45
266	A Phase I/II Study of Dose-Escalated Ifosfamide plus Carboplatin Combination for Advanced Ovarian Carcinoma. <i>Oncology Research and Treatment</i> , 1999, 22, 212-215.	1.2	0
267	<i>Candida catenulata</i> Fungemia in a Cancer Patient. <i>Journal of Clinical Microbiology</i> , 1999, 37, 475-477.	3.9	29
268	Paclitaxel-Anthracycline Combination Chemotherapy in Relapsing Advanced Ovarian Cancer after Platinum-Based Chemotherapy: A Pilot Study. <i>Gynecologic Oncology</i> , 1998, 70, 414-417.	1.4	9
269	An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome. <i>Journal of Infection</i> , 1998, 37, 173-180.	3.3	250
270	Prospective study of bacteraemia in cancer patients. <i>Supportive Care in Cancer</i> , 1998, 6, 273-280.	2.2	34

#	ARTICLE	IF	CITATIONS
271	Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. British Journal of Haematology, 1998, 103, 205-212.	2.5	279
272	A multivariate analysis of the survival of patients with aggressive lymphoma. Cancer, 1998, 82, 1952-1962.	4.1	7
273	Cefepime/Amikacin Versus Ceftazidime/Amikacin as Empirical Therapy for Febrile Episodes in Neutropenic Patients: A Comparative Study. Clinical Infectious Diseases, 1997, 24, 41-51.	5.8	93
274	Safety and efficacy of Intralipid emulsions of amphotericin B. Journal of Antimicrobial Chemotherapy, 1997, 40, 137-139.	3.0	5
275	International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clinical Infectious Diseases, 1997, 25, 43-59.	5.8	438
276	Post-traumatic intracranial epidural <i>Aspergillus fumigatus</i> abscess. Medical Mycology, 1997, 35, 279-282.	0.7	21
277	Placebo-Controlled phase III Study of lenograstim (Glycosylated recombinant human granulocyte) Tj ETQq1 1 0.784314 rgBT /Overload administration. Leukemia and Lymphoma, 1997, 25, 289-300.	1.3	90
278	Safety of amphotericin B colloidal dispersion. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 74-80.	2.9	26
279	A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British Journal of Haematology, 1997, 98, 711-718.	2.5	428
280	Facteurs de croissance et infection. Médecine Et Maladies Infectieuses, 1996, 26, 1129-1139.	5.0	1
281	Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.. Journal of Clinical Oncology, 1996, 14, 240-248.	1.6	22
282	Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Annals of Oncology, 1996, 7, 966-969.	1.2	29
283	Successful treatment of visceral leishmaniasis with high-dose amphotericin B diluted in fat emulsion: a case report. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 322-323.	1.8	3
284	Idarubicin and High Dose Cytarabine: A New Salvage Treatment for Refractory or Relapsing Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1996, 22, 329-334.	1.3	8
285	The Safety and Efficacy of Amphotericin B Colloidal Dispersion in the Treatment of Invasive Mycoses. Clinical Infectious Diseases, 1995, 21, 1145-1153.	5.8	140
286	Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.. Journal of Clinical Oncology, 1994, 12, 2543-2551.	1.6	192
287	Les infections À cocci À Gram positif en h�matologie et en cancérologie. Médecine Et Maladies Infectieuses, 1994, 24, 1222-1228.	5.0	7
288	Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. British Journal of Cancer, 1994, 70, 154-159.	6.4	36

#	ARTICLE	IF	CITATIONS
289	Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. Annals of Oncology, 1993, 4, 651-656.	1.2	152
290	Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. a study of the groupe d'etude des lymphomes agressifs. American Journal of Medicine, 1991, 90, 77-84.	1.5	129
291	Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.. Journal of Clinical Oncology, 1991, 9, 211-219.	1.6	217
292	Piperacillin and netilmicin combination therapy for febrile episodes in neutropenic patients. Infection, 1990, 18, 310-313.	4.7	3
293	Interactions of Cyclosporine with Antimicrobial Agents. Clinical Infectious Diseases, 1990, 12, 371-371.	5.8	4
294	LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.. Journal of Clinical Oncology, 1989, 7, 1018-1026.	1.6	247
295	VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen. Cancer Chemotherapy and Pharmacology, 1989, 24, 338-339.	2.3	7
296	Combination of recombinant interferon alpha-2A and vinblastine in advanced renal cell cancer. Cancer, 1988, 62, 2320-2324.	4.1	52
297	Azoles. , 0, , 417-434.		0